VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
Earnings for VolitionRx Limited (VNRX)
Earnings in 2023 (TTM): $-35,677,074
According to VolitionRx Limited's latest financial reports the company's current earnings (TTM) are $-35,677,074. The earnings displayed on this page is the company's Pretax Income.
Earnings history of VolitionRx Limited
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-35,677,074 | $-35,319,078 |
| 2022 | $-30,598,469 | $-30,268,793 |
| 2021 | $-26,989,781 | $-26,970,468 |
| 2020 | $-20,399,294 | $-20,481,914 |
| 2019 | $-16,099,055 | $-16,028,670 |
| 2018 | $-18,008,623 | $-18,008,623 |
| 2017 | $-14,769,207 | $-14,769,207 |
| 2016 | $-11,905,278 | $-11,905,278 |
| 2015 | $-9,534,846 | $-9,530,242 |
| 2014 | $-8,213,529 | $-8,213,529 |
| 2013 | $-3,710,289 | $-3,710,289 |
| 2012 | $-4,083,050 | $-4,083,050 |
| 2011 | $ | $-2,608,463 |
| 2010 | $-10,947 | $-10,947 |
| 2009 | $-15,816 | $-15,816 |
| 2008 | $ | $-21,803 |
| 2007 | $ | $-26,295 |
| 2006 | $ | $-36,987 |
| 2005 | $ | $-13,105 |
| 2004 | $ | $-24,180 |